Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants

被引:104
作者
Buckingham, SC
Bush, AJ
Devincenzo, JP
机构
[1] Lebonheur Childrens Med Ctr, Dept Pediat, Memphis, TN 38103 USA
[2] Univ Tennessee, Dept Pediat, Div Infect Dis, Memphis, TN USA
[3] Univ Tennessee, Dept Prevent Med, Div Biostat & Epidemiol, Memphis, TN USA
[4] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA
关键词
respiratory syncytial virus; quantitative viral culture; disease severity; respiratory failure;
D O I
10.1097/00006454-200002000-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective, To evaluate the relationship between nasal quantity of respiratory syncytial virus (RSV) and disease severity in hospitalized infants without underlying cardiopulmonary disease or immunodeficiency. Methods. Nasal aspirates were obtained from hospitalized infants <24 months of age with recently identified RSV infection and evaluated for RSV quantity by a standard plaque assay on HEp-2 cell monolayers. Subjects were classified as having "severe" disease if they required mechanical ventilation at the time of sample collection and as having "nonsevere" disease if they did not, Linear modeling was used to determine the relationship between nasal RSV quantity and various independent variables, including disease severity. Results, Nasal aspirates from 39 patients were evaluated, Age, gender and mean duration of time from symptom onset to sample acquisition (5 days) were similar between the severe (n = 15) and nonsevere (n = 24) groups. Significantly more infants were born at <35 weeks gestation in the severe disease group (7 of 15 vs. 3 of 24, P = 0.017), and infants born at <35 weeks gestation were significantly more likely to be of non-Caucasian ethnicity than were infants born at greater than or equal to 35 weeks gestation (8 of 10 vs. 12 of 29, P = 0.035), The linear model found that higher nasal RSV quantities were associated with severe disease [mean +/- SEM, 5.06 +/- 0.34 log plaque-forming units (pfu)/ml vs. 3.91 +/- 0.35 log pfu/ml, P = 0.022], gestational age greater than or equal to 35 weeks (5.44 +/- 0.27 log pfu/ml us. 3.52 +/- 0.45 log pfu/ml, P = 0.002) and non-Caucasian ethnicity (5.16 +/- 0.30 log pfu/ml vs. 3.80 +/- 0.37 log pfu/ml, P = 0.006). Conclusions. Nasal RSV quantity correlates with disease severity in hospitalized infants with recently identified RSV infection.
引用
收藏
页码:113 / 117
页数:5
相关论文
共 14 条
  • [1] RIBAVIRIN TREATMENT OF RESPIRATORY SYNCYTIAL VIRAL-INFECTION IN INFANTS WITH UNDERLYING CARDIOPULMONARY DISEASE
    HALL, CB
    MCBRIDE, JT
    GALA, CL
    HILDRETH, SW
    SCHNABEL, KC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1985, 254 (21): : 3047 - 3051
  • [2] HALL CB, 1976, J PEDIATR-US, V89, P11, DOI 10.1016/S0022-3476(76)80918-3
  • [3] AEROSOLIZED RIBAVIRIN TREATMENT OF INFANTS WITH RESPIRATORY SYNCYTIAL VIRAL-INFECTION - A RANDOMIZED DOUBLE-BLIND-STUDY
    HALL, CB
    MCBRIDE, JT
    WALSH, EE
    BELL, DM
    GALA, CL
    HILDRETH, S
    TENEYCK, LG
    HALL, WJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (24) : 1443 - 1447
  • [4] QUANTITATIVE SHEDDING PATTERNS OF RESPIRATORY SYNCYTIAL VIRUS IN INFANTS
    HALL, CB
    DOUGLAS, RG
    GEIMAN, JM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1975, 132 (02) : 151 - 156
  • [5] Halsey NA, 1998, PEDIATRICS, V102, P1211, DOI 10.1542/peds.102.5.1211
  • [6] INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS-INFECTIONS IN INFANTS AND YOUNG-CHILDREN
    HEMMING, VG
    RODRIGUEZ, W
    KIM, HW
    BRANDT, CD
    PARROTT, RH
    BURCH, B
    PRINCE, GA
    BARON, PA
    FINK, RJ
    REAMAN, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (12) : 1882 - 1886
  • [7] LOWTHER SA, 1998, CLIN INFECT DIS, V27, P1062
  • [8] Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein
    Malley, R
    DeVincenzo, J
    Ramilo, O
    Dennehy, PH
    Meissner, HC
    Gruber, WC
    Sanchez, PJ
    Jafri, H
    Balsley, J
    Carlin, D
    Buckingham, S
    Vernacchio, L
    Ambrosino, DM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (06) : 1555 - 1561
  • [9] AEROSOLIZED RIBAVIRIN IN MECHANICALLY VENTILATED CHILDREN WITH RESPIRATORY SYNCYTIAL VIRUS LOWER RESPIRATORY-TRACT DISEASE - A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED TRIAL
    MEERT, KL
    SARNAIK, AP
    GELMINI, MJ
    LIEHLAI, MW
    [J]. CRITICAL CARE MEDICINE, 1994, 22 (04) : 566 - 572
  • [10] Ribavirin for respiratory syncytial virus lower respiratory tract infection - A systematic overview
    Randolph, AG
    Wang, EEL
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1996, 150 (09): : 942 - 947